BioSpace News Archive

Policy

Biogen Sees Rocky 2022 Finish with Further Aduhelm, Lecanemab Scrutiny

Two documents recently came to light: first, the results of a congressional investigation into the approval of Aduhelm; second, a revised clinical trial consent form for lecanemab.

January 3, 2023
·
3 min read
·
Heather McKenzie
Business

Gilead, EVOQ Unite on ‘Potential Breakthrough’ Treatment for RA, Lupus

Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.

January 3, 2023
·
2 min read
·
Rosemary Scott
Policy

Aurinia and Sun Pharma File Joint Motion to Settle Patent Dispute

Aurinia and Sun Pharma agree to file a joint motion to dismiss a key patent dispute.

January 3, 2023
·
2 min read
·
George Budwell
Drug Development

Chemomab Claims Mid-Stage Win in NASH

Chemomab’s experimental antibody shows promise in NASH.

January 3, 2023
·
2 min read
·
Tristan Manalac
Point-of-Care Testing (POCT) Market Size To Attain USD 103.2 Bn By 2030

The global point-of-care testing (POCT) market size accounted for USD 45.03 billion in 2022 and is expected to attain around USD 103.2 billion by 2030 with a noteworthy CAGR of 10.92% from 2022 to 2030.

January 3, 2023
·
8 min read
Business

Verismo Therapeutics Expands Quality and Compliance Team

Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, announced that Jacqueline Stief has joined as the new Head of Quality and Compliance.

January 3, 2023
·
3 min read
Immunotherapy Drugs Market Size to Reach US$ 351.56 BN by 2030

The global immunotherapy drugs market size is expected to reach around US$ 351.56 billion by 2030 and it is anticipated to grow at a CAGR of 7.9% between 2022 to 2030.

January 3, 2023
·
7 min read
Head and Neck Cancer Drugs Market Size to Surpass US$ 2.99 BN by 2030

The global head and neck cancer drugs market size is expected to surpass around US$ 2.99 billion by 2030 and predicted to grow at a compound annual growth rate (CAGR) of 7.9% between 2022 to 2030.

January 3, 2023
·
8 min read
Job Trends

Mantra Pharma in Action - Mantra Pharma Introduces the First Generic Alternative to CLAVULIN® (GSK) in Canada

Following an increase in cases of respiratory viruses, Canada is currently experiencing supply issues for an oral antibiotic for children, the CLAVULIN® from GSK.

January 3, 2023
·
1 min read
Drug Development

Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain

WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain.

January 3, 2023
·
6 min read